Future studies are needed to determine the role of bridging RT before CD19 CART as a strategy to improve outcomes and prevent early relapse in patients with R/R B-cell NHL at high risk of progression. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.